We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Journey Medical Corporation | NASDAQ:DERM | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.14 | -3.79% | 3.55 | 3.52 | 3.95 | 3.74 | 3.51 | 3.68 | 51,318 | 00:21:25 |
From May 2019 to May 2024
By Stephen Nakrosis
Shares of biopharmaceutical company Dermira Inc. (DERM) are trading higher on the Nasdaq Friday with heavy volume, following news Eli Lilly and Co. (LLY) agreed to buy the company in a $1.1 billion deal.
At 11:50 a.m. EST, Dermira shares had gained 4.74% to trade at $19.21. Volume topped 21 million shares, above the 65-day average volume of some 1.5 million shares.
Earlier in the session, Dermira shares touched a 52-week high of $19.48.
Eli Lilly shares were trading 1.13% higher, at $137.45. They touched a 52-week high of $137.63 earlier in the session.
Before the bell Friday, Lilly said it planned to buy Dermira for $18.75 per share. Dermira is developing therapies for skin conditions, including lebrikizumab, which is being evaluated for the treatment of moderate-to-severe atopic dermatitis in patients 12 and older.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
January 10, 2020 12:10 ET (17:10 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Journey Medical Chart |
1 Month Journey Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
